CtIP, a multivalent adaptor connecting transcriptional regulation, checkpoint control and tumor suppression

Cell Cycle

Volumn 5, Issue 15, 2006, Pages 1592-1596

  Wu, Guikai ^a   Lee, Wen Hwa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Checkpoint; CtIP; Rb E2F pathway; Review; Tumor suppression

Indexed keywords

BINDING PROTEIN; PHOSPHOPROTEIN; PROTEIN CTBP; PROTEIN CTLP; REPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

CANCER CONTROL; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; DNA DAMAGE; DNA REPLICATION; DRUG ACTIVITY; GENE DOSAGE; HAPLOIDY; HUMAN; REVIEW; TRANSCRIPTION REGULATION;

EID: 33747837752     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.15.3127     Document Type: Review

References (55)

1. Fusco C, Reymond A, Zervos AS. Molecular cloning and characterization of a novel retinoblastoma-binding protein. Genomics 1998; 51:351-8.
2. Schaeper U, Subramanian T, Lim L, Boyd JM, Chinnadurai G. Interaction between a cellular protein that binds to the C-terminal region of adenovirus E1A (CtBP) and a novel cellular protein is disrupted by E1A through a conserved PLDLS motif. J Biol Chem 1998; 273:8549-52.
3. Meloni AR, Smith EJ, Nevins JR. A mechanism for Rb/p130-mediated transcription repression involving recruitment of the CtBP corepressor. Proc Natl Acad Sci USA 1999; 96:9574-9.
4. Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 1998; 273:25388-92.
5. Wong AK, Ormonde PA, Pero R, Chen Y, Lian L, Salada G, Berry S, Lawrence Q, Dayananth P, Ha P, Tavtigian SV, Teng DH, Bartel PL. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 1998; 17:2279-85.
6. Li S, Chen PL, Subramanian T, Chinnadurai G, Tomlinson G, Osborne CK, Sharp ZD, Lee WH. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem 1999; 274:11334-8.
7. Yu X, Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 2004; 24:9478-86.
8. Li S, Ting NS, Zheng L, Chen PL, Ziv Y, Shiloh Y, Lee EY, Lee WH. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 2000; 406:210-5.
9. Yu X, Baer R. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J Biol Chem 2000; 275:18541-9.
10. Nibu Y, Zhang H, Levine M. Interaction of short-range repressors with Drosophila CtBP in the embryo. Science 1998; 280:101-4.
11. Poortinga G, Watanabe M, Parkhurst SM. Drosophila CtBP: A Hairy-interacting protein required for embryonic segmentation and hairy-mediated transcriptional repression. Embo J 1998; 17:2067-78.
12. Furusawa T, Moribe H, Kondoh H, Higashi Y. Identification of CtBP1 and CtBP2 as corepressors of zinc finger-homeodomain factor deltaEF1. Mol Cell Biol 1999; 19:8581-90.
13. Postigo AA, Dean DC. ZEB represses transcription through interaction with the corepressor CtBP. Proc Natl Acad Sci USA 1999; 96:6683-8.
14. Koipally J, Georgopoulos K. Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. J Biol Chem 2000; 275:19594-602.
15. Palmer S, Brouillet JP, Kilbey A, Fulton R, Walker M, Crossley M, Bartholomew C. Evi-1 transforming and repressor activities are mediated by CtBP corepressor proteins. J Biol Chem 2001; 276:25834-40.
16. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ. Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 2001; 75:7749-55.
17. Vo N, Fjeld C, Goodman RH. Acetylation of nuclear hormone receptor-interacting protein RIP140 regulates binding of the transcriptional corepressor CtBP. Mol Cell Biol 2001; 21:6181-8.
18. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ. Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the corepressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 2002; 277:47197-204.
19. Lin X, Liang YY, Sun B, Liang M, Shi Y, Brunicardi FC, Feng XH. Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription. Mol Cell Biol 2003; 23:9081-93.
20. Kim JH, Cho EJ, Kim ST, Youn HD. CtBP represses p300-mediated transcriptional activation by direct association with its bromodomain. Nat Struct Mol Biol 2005; 12:423-8.
21. Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, Lan F, Ogawa H, Luke MP, Nakatani Y. Coordinated histone modifications mediated by a CtBP corepressor complex. Nature 2003; 422:735-8.
22. Sewalt RG, Gunster MJ, van der Vlag J, Satijn DP, Otte AP. C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. Mol Cell Biol 1999; 19:777-87.
23. Atchison L, Ghias A, Wilkinson F, Bonini N, Atchison ML. Transcription factor YY1 functions as a PcG protein in vivo. Embo J 2003; 22:1347-58.
24. Sum EY, Peng B, Yu X, Chen J, Byrne J, Lindeman GJ, Visvader JE. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J Biol Chem 2002; 277:7849-56.
25. Furuta S, Wang JM, Wei S, Jeng YM, Jiang X, Gu B, Chen PL, Lee EY, Lee WH. Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell 2006; 10:13-4.
26. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, Livingston DM. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 2006; 20:34-46.
27. Chen PL, Liu F, Cai S, Lin X, Li A, Chen Y, Gu B, Lee EY, Lee WH. Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency. Mol Cell Biol 2005; 25:3535-42.
28. Liu F, Lee WH. CtIP activates its own and cyclin D1 promoters via the E2F/RB pathway during G1/S progression. Mol Cell Biol 2006; 26:3124-34.
29. 1-specific transcription via phosphorylation of the SBF bound repressor Whi5. Cell 2004; 117:887-98.
30. 1/S transcription in yeast. Cell 2004; 117:899-913.
31. Royzman I, Austin RJ, Bosco G, Bell SP, Orr-Weaver TL. ORC localization in Drosophila follicle cells and the effects of mutations in dE2F and dDP. Genes Dev 1999; 13:827-40.
32. Bosco G, Du W, Orr-Weaver TL. DNA replication control through interaction of E2F-RB and the origin recognition complex. Nat Cell Biol 2001; 3:289-95.
33. Takemura M, Kitagawa T, Izuta S, Wasa J, Takai A, Akiyama T, Yoshida S. Phosphorylated retinoblastoma protein stimulates DNA polymerase alpha. Oncogene 1997; 15:2483-92.
34. Sterner JM, Dew-Knight S, Musahl C, Kornbluth S, Horowitz JM. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol Cell Biol 1998; 18:2748-57.
35. Pennaneach V, Salles-Passador I, Munshi A, Brickner H, Regazzoni K, Dick F, Dyson N, Chen TT, Wang JY, Fotedar R, Fotedar A. The large subunit of replication factor C promotes cell survival after DNA damage in an LxCxE motif- and Rb-dependent manner. Mol Cell 2001; 7:715-27.
36. Sever-Chroneos Z, Angus SP, Fribourg AF, Wan H, Todorov I, Knudsen KE, Knudsen ES. Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Mol Cell Biol 2001; 21:4032-45.
37. Angus SP, Mayhew CN, Solomon DA, Braden WA, Markey MP, Okuno Y, Cardoso MC, Gilbert DM, Knudsen ES. RB reversibly inhibits DNA replication via two temporally distinct mechanisms. Mol Cell Biol 2004; 24:5404-20.
38. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, Firestein R, Cleary M, Jenuwein T, Herrera RE, Kouzarides T. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001; 412:561-5.
39. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000; 25:338-42.
40. Pradhan S, Kim GD. The retinoblastoma gene product interacts with maintenance human DNA (cytosine-5) methyltransferase and modulates its activity. Embo J 2002; 21:779-88.
41. Eskiw CH, Bazett-Jones DP. The promyelocytic leukemia nuclear body: Sites of activity? Biochem Cell Biol 2002; 80:301-10.
42. Hatta M, Fukamizu A. PODs in the nuclear spot: Enigmas in the magician's pot. Sci STKE 2001; 2001:PE1.
43. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. Embo J 1998; 17:4657-67.
44. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396:177-80.
45. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 2001; 15:2934-9.
46. Bockmuhl U, Schluns K, Kuchler I, Petersen S, Petersen I. Genetic imbalances with impact on survival in head and neck cancer patients. Am J Pathol 2000; 157:369-75.
47. Knosel T, Schluns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I. Genetic imbalances with impact on survival in colorectal cancer patients. Histopathology 2003; 43:323-31.
48. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91:12823-7.
49. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85:537-48.
50. DeGregori J. The genetics of the E2F family of transcription factors: Shared functions and unique roles. Biochim Biophys Acta 2002; 1602:131-50.
51. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003; 3:807-21.
52. Radtke F, Raj K. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer 2003; 3:756-67.
53. Blyth K, Cameron ER, Neil JC. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 2005; 5:376-87.
54. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 2006; 6:11-23.
55. Chinnadurai G. CtIP, a candidate tumor susceptibility gene is a team player with luminaries. Biochim Biophys Acta 2006; 1765:67-73.